A New Publication Highlights the Use of cResponse in the Assessment of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer
A recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and PARPi therapy, exploring the genomic...
Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at the AACR Meeting in Orlando, Florida
Curesponse, a commercial-stage precision oncology company, presented preliminary clinical results from a multi-center UK Study at the American Association for Cancer Research (AACR) meeting in...